MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

493.89 -2.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

492.34

Max

511.43

Põhinäitajad
By Trading Economics
Sissetulek	-72M -114M
Müük	74M 287M
Kasumimarginaal	-39.75
Töötajad	528
EBITDA	-68M -106M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+24.62% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	2.4B 12B
Eelmine avamishind	496.48
Eelmine sulgemishind	493.89

Uudiste sentiment

By Acuity

50%

183 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. jaan 2026, 19:05 UTC

Suurimad hinnamuutused turgudel

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. jaan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. jaan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. jaan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. jaan 2026, 23:13 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. jaan 2026, 23:10 UTC

Omandamised, ülevõtmised, äriostud

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. jaan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. jaan 2026, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. jaan 2026, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. jaan 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. jaan 2026, 21:08 UTC

Omandamised, ülevõtmised, äriostud

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. jaan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. jaan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. jaan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. jaan 2026, 19:03 UTC

Tulu

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. jaan 2026, 18:50 UTC

Tulu

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. jaan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

13. jaan 2026, 17:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. jaan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. jaan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

13. jaan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. jaan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

24.62% tõus

12 kuu keskmine prognoos

Keskmine 636.22 USD 24.62%

Kõrge 900 USD

Madal 527 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

183 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.